Lung Ultrasound and Pulmonary Congestion During Stress Echocardiography.


Journal

JACC. Cardiovascular imaging
ISSN: 1876-7591
Titre abrégé: JACC Cardiovasc Imaging
Pays: United States
ID NLM: 101467978

Informations de publication

Date de publication:
10 2020
Historique:
received: 26 02 2020
revised: 22 04 2020
accepted: 30 04 2020
pubmed: 20 7 2020
medline: 12 8 2021
entrez: 20 7 2020
Statut: ppublish

Résumé

The purpose of this study was to assess the functional and prognostic correlates of B-lines during stress echocardiography (SE). B-profile detected by lung ultrasound (LUS) is a sign of pulmonary congestion during SE. The authors prospectively performed transthoracic echocardiography (TTE) and LUS in 2,145 patients referred for exercise (n = 1,012), vasodilator (n = 1,054), or dobutamine (n = 79) SE in 11 certified centers. B-lines were evaluated in a 4-site simplified scan (each site scored from 0: A-lines to 10: white lung for coalescing B-lines). During stress the following were also analyzed: stress-induced new regional wall motion abnormalities in 2 contiguous segments; reduced left ventricular contractile reserve (peak/rest based on force, ≤2.0 for exercise and dobutamine, ≤1.1 for vasodilators); and abnormal coronary flow velocity reserve ≤2.0, assessed by pulsed-wave Doppler sampling in left anterior descending coronary artery and abnormal heart rate reserve (peak/rest heart rate) ≤1.80 for exercise and dobutamine (≤1.22 for vasodilators). All patients completed follow-up. According to B-lines at peak stress patients were divided into 4 different groups: group I, absence of stress B-lines (score: 0 to 1; n = 1,389; 64.7%); group II, mild B-lines (score: 2 to 4; n = 428; 20%); group III, moderate B-lines (score: 5 to 9; n = 209; 9.7%) and group IV, severe B-lines (score: ≥10; n = 119; 5.4%). During median follow-up of 15.2 months (interquartile range: 12 to 20 months) there were 38 deaths and 28 nonfatal myocardial infarctions in 64 patients. At multivariable analysis, severe stress B-lines (hazard ratio [HR]: 3.544; 95% confidence interval [CI]: 1.466 to 8.687; p = 0.006), abnormal heart rate reserve (HR: 2.276; 95% CI: 1.215 to 4.262; p = 0.010), abnormal coronary flow velocity reserve (HR: 2.178; 95% CI: 1.059 to 4.479; p = 0.034), and age (HR: 1.031; 95% CI: 1.002 to 1.062; p = 0.037) were independent predictors of death and nonfatal myocardial infarction. Severe stress B-lines predict death and nonfatal myocardial infarction. (Stress Echo 2020-The International Stress Echo Study [SE2020]; NCT03049995).

Sections du résumé

OBJECTIVES
The purpose of this study was to assess the functional and prognostic correlates of B-lines during stress echocardiography (SE).
BACKGROUND
B-profile detected by lung ultrasound (LUS) is a sign of pulmonary congestion during SE.
METHODS
The authors prospectively performed transthoracic echocardiography (TTE) and LUS in 2,145 patients referred for exercise (n = 1,012), vasodilator (n = 1,054), or dobutamine (n = 79) SE in 11 certified centers. B-lines were evaluated in a 4-site simplified scan (each site scored from 0: A-lines to 10: white lung for coalescing B-lines). During stress the following were also analyzed: stress-induced new regional wall motion abnormalities in 2 contiguous segments; reduced left ventricular contractile reserve (peak/rest based on force, ≤2.0 for exercise and dobutamine, ≤1.1 for vasodilators); and abnormal coronary flow velocity reserve ≤2.0, assessed by pulsed-wave Doppler sampling in left anterior descending coronary artery and abnormal heart rate reserve (peak/rest heart rate) ≤1.80 for exercise and dobutamine (≤1.22 for vasodilators). All patients completed follow-up.
RESULTS
According to B-lines at peak stress patients were divided into 4 different groups: group I, absence of stress B-lines (score: 0 to 1; n = 1,389; 64.7%); group II, mild B-lines (score: 2 to 4; n = 428; 20%); group III, moderate B-lines (score: 5 to 9; n = 209; 9.7%) and group IV, severe B-lines (score: ≥10; n = 119; 5.4%). During median follow-up of 15.2 months (interquartile range: 12 to 20 months) there were 38 deaths and 28 nonfatal myocardial infarctions in 64 patients. At multivariable analysis, severe stress B-lines (hazard ratio [HR]: 3.544; 95% confidence interval [CI]: 1.466 to 8.687; p = 0.006), abnormal heart rate reserve (HR: 2.276; 95% CI: 1.215 to 4.262; p = 0.010), abnormal coronary flow velocity reserve (HR: 2.178; 95% CI: 1.059 to 4.479; p = 0.034), and age (HR: 1.031; 95% CI: 1.002 to 1.062; p = 0.037) were independent predictors of death and nonfatal myocardial infarction.
CONCLUSIONS
Severe stress B-lines predict death and nonfatal myocardial infarction. (Stress Echo 2020-The International Stress Echo Study [SE2020]; NCT03049995).

Identifiants

pubmed: 32682714
pii: S1936-878X(20)30410-1
doi: 10.1016/j.jcmg.2020.04.020
pii:
doi:

Substances chimiques

Dobutamine 3S12J47372

Banques de données

ClinicalTrials.gov
['NCT03049995']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2085-2095

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Auteurs

Maria Chiara Scali (MC)

Cardiothoracic Department, University of Pisa, and Nottola Cardiology Division, Montepulciano, Siena, Italy.

Angela Zagatina (A)

Cardiology Department, Saint Petersburg University Clinic, Saint Petersburg, Russian Federation.

Quirino Ciampi (Q)

Cardiology Division, Fatebenefratelli Hospital, Benevento, Italy.

Lauro Cortigiani (L)

Cardiology Department, San Luca Hospital, Lucca, Italy.

Antonello D'Andrea (A)

Cardiology Department, Echocardiography Lab and Rehabilitation Unit, Monaldi Hospital, Second University of Naples, Naples, Italy.

Clarissa Borguezan Daros (CB)

Cardiology Division, Hospital San José, Criciuma, Brasil.

Nadezhda Zhuravskaya (N)

Cardiology Department, Saint Petersburg University Clinic, Saint Petersburg, Russian Federation.

Jaroslaw D Kasprzak (JD)

Chair of Cardiology, Bieganski Hospital, Medical University, Lodz, Poland.

Karina Wierzbowska-Drabik (K)

Chair of Cardiology, Bieganski Hospital, Medical University, Lodz, Poland.

José Luis de Castro E Silva Pretto (J)

Hospital Sao Vicente de Paulo e Hospital de Cidade, Passo Fundo, Brasil.

Ana Djordjevic-Dikic (A)

Cardiology Clinic, Clinical Center of Serbia, Medical School, University of Belgrade, Belgrade, Serbia.

Branko Beleslin (B)

Cardiology Clinic, Clinical Center of Serbia, Medical School, University of Belgrade, Belgrade, Serbia.

Marija Petrovic (M)

Cardiology Clinic, Clinical Center of Serbia, Medical School, University of Belgrade, Belgrade, Serbia.

Nikola Boskovic (N)

Cardiology Clinic, Clinical Center of Serbia, Medical School, University of Belgrade, Belgrade, Serbia.

Milorad Tesic (M)

Cardiology Clinic, Clinical Center of Serbia, Medical School, University of Belgrade, Belgrade, Serbia.

Ines Monte (I)

Cardio-Thorax-Vascular Department, Echocardiography lab, "Policlinico Vittorio Emanuele", Catania University, Catania, Italy.

Iana Simova (I)

Head of Cardiology Department, Acibadem City Clinic Cardiovascular Center, University Hospital, Sofia, Bulgaria.

Martina Vladova (M)

Head of Cardiology Department, Acibadem City Clinic Cardiovascular Center, University Hospital, Sofia, Bulgaria.

Alla Boshchenko (A)

Cardiology Research Institute, Tomsk National Research Medical Centre of the Russian Academy of Sciences, Tomsk, Russian Federation.

Alexander Vrublevsky (A)

Cardiology Research Institute, Tomsk National Research Medical Centre of the Russian Academy of Sciences, Tomsk, Russian Federation.

Rodolfo Citro (R)

Cardiology Department and Echocardiography Lab, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy.

Miguel Amor (M)

Cardiology Department, Ramos Mejia Hospital, Buenos Aires, Argentina.

Paul E Vargas Mieles (PE)

Cardiology Department, Ramos Mejia Hospital, Buenos Aires, Argentina.

Rosina Arbucci (R)

Cardiodiagnosticos, Investigaciones Medicas, Buenos Aires, Argentina.

Pablo Martin Merlo (PM)

Cardiodiagnosticos, Investigaciones Medicas, Buenos Aires, Argentina.

Diego M Lowenstein Haber (DM)

Cardiodiagnosticos, Investigaciones Medicas, Buenos Aires, Argentina.

Claudio Dodi (C)

Casa di Cura Figlie di San Camillo, Cremona, Italy.

Fausto Rigo (F)

Cardiology Department, Ospedale dell'Angelo Mestre-Venice, Venice, Italy.

Suzana Gligorova (S)

Cardiology Division Ospedale Casilino, Roma, Italy.

Milica Dekleva (M)

Clinical Cardiology Department, Clinical Hospital Zvezdara, Medical School, University of Belgrade, Belgrade, Serbia.

Sergio Severino (S)

Cardiology Department, Coronary Care Unit, Monaldi Hospital, Second University of Naples, Naples, Italy.

Fabio Lattanzi (F)

Cardiothoracic Department, University of Pisa, and Nottola Cardiology Division, Montepulciano, Siena, Italy.

Doralisa Morrone (D)

Cardiothoracic Department, University of Pisa, and Nottola Cardiology Division, Montepulciano, Siena, Italy.

Maurizio Galderisi (M)

Department of Advanced Biomedical Sciences, Federico II University Hospital, Naples, Italy.

Marco A R Torres (MAR)

Hospital de Clinicas de Porto Alegre - Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.

Alessandro Salustri (A)

Non-invasive Cardiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.

Hugo Rodrìguez-Zanella (H)

Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico.

Fabio Marco Costantino (FM)

Cardiology Department, San Carlo Hospital, Potenza, Italy.

Albert Varga (A)

Institute of Family Medicine, University of Szeged, Szeged, Hungary.

Gergely Agoston (G)

Institute of Family Medicine, University of Szeged, Szeged, Hungary.

Eduardo Bossone (E)

Azienda Ospedaliera Rilevanza Nazionale A. Cardarelli Hospital, Naples, Italy.

Francesco Ferrara (F)

Azienda Ospedaliera Rilevanza Nazionale A. Cardarelli Hospital, Naples, Italy.

Nicola Gaibazzi (N)

Cardiology Department, Parma University Hospital, Parma, Italy.

Jelena Celutkiene (J)

Centre of Cardiology and Angiology, Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.

Maciej Haberka (M)

Department of Cardiology, SHS, Medical University of Silesia, Katowice, Poland.

Fabio Mori (F)

SOD Diagnostica Cardiovascolare, DAI Cardio-Toraco-Vascolare, Azienda Ospedaliera-Universitaria Careggi, Florence, Italy.

Maria Grazia D'Alfonso (MG)

SOD Diagnostica Cardiovascolare, DAI Cardio-Toraco-Vascolare, Azienda Ospedaliera-Universitaria Careggi, Florence, Italy.

Barbara Reisenhofer (B)

Cardiology Division, Pontedera-Volterra Hospital, ASL Toscana Nord-Ovest, Italy.

Ana Cristina Camarozano (AC)

Hospital de Clinicas UFPR, Medicine Department, Federal University of Paranà, Curitiba, Brazil.

Marcelo Haertel Miglioranza (MH)

Institute of Cardiology / University Foundation of Cardiology, Porto Alegre, Brazil.

Ewa Szymczyk (E)

Chair of Cardiology, Bieganski Hospital, Medical University, Lodz, Poland.

Paulina Wejner-Mik (P)

Chair of Cardiology, Bieganski Hospital, Medical University, Lodz, Poland.

Katarzyna Wdowiak-Okrojek (K)

Chair of Cardiology, Bieganski Hospital, Medical University, Lodz, Poland.

Tamara Preradovic-Kovacevic (T)

School of Medicine, University Clinical Center of The Republic of Srpska, Banja-Luka, Bosnia-Herzegovina.

Tonino Bombardini (T)

School of Medicine, University Clinical Center of The Republic of Srpska, Banja-Luka, Bosnia-Herzegovina.

Miodrag Ostojic (M)

School of Medicine, Institute for Cardiovascular Disease Dedinje, Belgrade, Serbia.

Aleksandra Nikolic (A)

School of Medicine, Institute for Cardiovascular Disease Dedinje, Belgrade, Serbia.

Federica Re (F)

Ospedale San Camillo, Cardiology Division, Rome, Italy.

Andrea Barbieri (A)

Cardiology Division, Policlinico University Hospital of Modena, Modena, Italy.

Giovanni Di Salvo (G)

Pediatric Cardiology Department, Cardiology Division, Brompton Hospital, Imperial College of London, London, United Kingdom.

Elisa Merli (E)

Department of Cardiology, Ospedale per gli Infermi, Faenza, Ravenna, Italy.

Paolo Colonna (P)

Cardiology Hospital, Policlinico University Hospital of Bari, Bari, Italy.

Valentina Lorenzoni (V)

Institute of Management, Scuola Superiore Sant'Anna, Pisa, Italy.

Michele De Nes (M)

CNR, Institute of Clinical Physiology, Biomedicine Department, Pisa, Italy.

Marco Paterni (M)

CNR, Institute of Clinical Physiology, Biomedicine Department, Pisa, Italy.

Clara Carpeggiani (C)

CNR, Institute of Clinical Physiology, Biomedicine Department, Pisa, Italy.

Jorge Lowenstein (J)

Cardiodiagnosticos, Investigaciones Medicas, Buenos Aires, Argentina.

Eugenio Picano (E)

CNR, Institute of Clinical Physiology, Biomedicine Department, Pisa, Italy. Electronic address: picano@ifc.cnr.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH